Opendata, web and dolomites

Hypo-RESOLVE SIGNED

Hypoglycaemia - REdefining SOLutions for better liVEs

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Hypo-RESOLVE project word cloud

Explore the words cloud of the Hypo-RESOLVE project. It provides you a very rough idea of what is the project "Hypo-RESOLVE" about.

threshold    constitutes    translational    psychological    databases    patient    impaired    classification    10    decreases    million    data    below    restoration    basic    valuable    event    quantify    mechanisms    150    complications    diseases    cgm    treatment    individual    barrier    whom    hypoglycaemia    economic    health    outcomes    resolve    power    elevated    detected    communicable    global    science    normalising    clinic    clinical    mortality    poor    events    insulin    microvascular    creates    life    alleviate    altogether    diabetic    private    public    cognitive    decline    significance    huge    regulators    statistical    principal    glucose    line    chronic    questions    partnership    prevents    underlying    secure    symptoms    reduce    impacts    lives    trials    people    society    construct    stakeholders    input    patients    populations    hyperglycaemia    quality    sustainable    levels    prevent    risk    epidemiologic    hypo    diabetes    answering    improves    burden    saves    serious    explore    cardiovascular    kin    prevalent   

Project "Hypo-RESOLVE" data sheet

The following table provides information about the project.

Coordinator
STICHTING KATHOLIEKE UNIVERSITEIT 

Organization address
address: GEERT GROOTEPLEIN NOORD 9
city: NIJMEGEN
postcode: 6525 EZ
website: www.radboudumc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website https://hypo-resolve.eu/
 Total cost 26˙774˙582 €
 EC max contribution 13˙450˙057 € (50%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2016-10-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2022-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) coordinator 2˙301˙983.00
2    THE UNIVERSITY OF SHEFFIELD UK (SHEFFIELD) participant 1˙990˙508.00
3    SYDDANSK UNIVERSITET DK (ODENSE M) participant 1˙354˙981.00
4    THE UNIVERSITY OF EDINBURGH UK (EDINBURGH) participant 1˙351˙453.00
5    REGION HOVEDSTADEN DK (HILLEROD) participant 1˙030˙750.00
6    UNIVERSITE DE LAUSANNE CH (LAUSANNE) participant 955˙601.00
7    SIB INSTITUT SUISSE DE BIOINFORMATIQUE CH (GENEVE) participant 934˙250.00
8    MEDIZINISCHE UNIVERSITAT GRAZ AT (GRAZ) participant 800˙000.00
9    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 661˙202.00
10    EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH DE (ST INGBERT) participant 502˙125.00
11    CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER FR (MONTPELLIER) participant 465˙000.00
12    UNIVERSITA DEGLI STUDI DI PADOVA IT (PADOVA) participant 392˙687.00
13    UNIVERSITY OF DUNDEE UK (DUNDEE) participant 383˙622.00
14    KING'S COLLEGE LONDON UK (LONDON) participant 325˙891.00
15    ABBOTT DIABETES CARE US (ALAMEDA) participant 0.00
16    Eli Lilly and Company Limited UK (Basingstoke) participant 0.00
17    FEDERATION INTERNATIONALE DU DIABETE BE (BRUXELLES) participant 0.00
18    JDRF INTERNATIONAL US (NEW YORK) participant 0.00
19    MEDTRONIC INTERNATIONAL TRADING SARL CH (TOLOCHENAZ) participant 0.00
20    NOVO NORDISK A/S DK (BAGSVAERD) participant 0.00
21    SANOFI-AVENTIS DEUTSCHLAND GMBH DE (FRANKFURT AM MAIN) participant 0.00
22    THE LEONA M. AND HARRY B. HELMSLEY CHARITABLE TRUST US (NEW YORK) participant 0.00
23    UNITIO INC US (BOSTON) participant 0.00

Map

 Project objective

Diabetes is one of the most prevalent global non-communicable diseases, affecting 60 million people in Europe, 10% of whom with type 1 diabetes. Normalising elevated glucose levels decreases symptoms, prevents microvascular complications, improves cardiovascular health and saves lives, but creates a significant risk for hypoglycaemia when insulin treatment is required. Hypoglycaemia is a serious event associated with cognitive decline, reduced quality of life, cardiovascular events and mortality. Hypoglycaemia remains the principal barrier to achieve glucose levels necessary to prevent diabetic complications of chronic hyperglycaemia. The overall objective of Hypo-RESOLVE is to alleviate the burden and consequences of hypoglycaemia, to be achieved by answering several key questions through a unique public-private partnership. Hypo-RESOLVE will construct secure sustainable databases with data from 100-150 clinical trials offering huge statistical power to establish the glucose threshold(s) below which hypoglycaemia constitutes a risk for poor outcomes in various populations. This will provide valuable input for an evidence based classification of hypoglycaemia to be adopted by regulators, patient organisations and other stakeholders, for application in future trials, the clinic and epidemiologic studies. The basic science and translational research line of Hypo-RESOLVE will advance our understanding on mechanisms underlying consequences of hypoglycaemia and explore novel pathways for the restoration of impaired awareness of hypoglycaemia. Finally, we will determine the significance of CGM-detected low glucose and investigate psychological and economic impacts of hypoglycaemia to quantify the burden of hypoglycaemia both for the individual and next-of-kin, as well as for society. Altogether, Hypo-RESOLVE will importantly further our knowledge of hypoglycaemia, (facilitate to) reduce its burden and contribute to a better life for patients with insulin-treated diabetes

 Deliverables

List of deliverables.
Updated review of the evidence surrounding our proposed classification Documents, reports 2020-02-18 10:16:24
External Project Website Websites, patent fillings, videos etc. 2020-02-18 10:16:25
Hypo-RESOLVE Position Paper Documents, reports 2020-02-18 10:16:25

Take a look to the deliverables list in detail:  detailed list of Hypo-RESOLVE deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HYPO-RESOLVE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HYPO-RESOLVE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriNTM (2019)

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Read More  

TRIC-TB (2019)

Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments.

Read More  

PD-MIND (2019)

Parkinson Disease with Mild cognition Impairment treated with Nicotinic agonist Drug

Read More